Skip to main content
Fig. 2 | Lipids in Health and Disease

Fig. 2

From: Adeno-associated virus-based caveolin-1 delivery via different routes for the prevention of cholesterol gallstone formation

Fig. 2

AAV2/8 CAV1 treatment via the i.p. route can partially prevent CGD in LD-fed mice through the biliary CSI-independent pathway

Mice were injected (either via the i.v. or i.p. route) with or without AAV2/8CAV1 at 1 × 1011 vg/animal and then fed LD following PBS or compound c treatment (8 weeks). n = 13 for each group, LD-fed mice with either i.v. or i.p. administration of AAV2/8CAV1 with or without compound c treatment (10 mg/kg, i.p. injection once a day); n = 9 for LD-fed mice (control) with neither AAV2/8CAV1 administration nor compound c treatment

The letters on each bar are provided for statistical purposes, and different letters indicate significance (P < 0.05). If there are no significant differences between two bars, they have the same letter. The individual P values are described in Supplementary Table 3.

A. Lithogenic diet mass consumed by each group of mice.

B. qRT‒PCR analysis of the liver, gallbladder, and ileum messenger RNA expression of cholesterol, phospholipid transporters, and bile acid transporters in each group of mice. 18 S rRNA was used as an internal control. Data represent the mean ± SD.

C. Twenty-four-hour cumulative fecal samples collected from each group of mice were pooled and measured for total cholesterol contents.

D. Biliary concentrations of cholesterol, phospholipids, bile acid, and CSI in each group of mice.

E. Polarizing light microscopy examination of cholesterol crystals in the gallbladder of each group of mice. i.v., AAV2/8CAV1 injection (1 × 1011 vg/mice) via the i.v. route; i.p., AAV2/8CAV1 injection (1 × 1011 vg/mice) via the i.p. route.

Back to article page